System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Carsten Bokemeyer is an expert in Oncology at University Medical Center Hamburg-Eppendorf (Germany). As of October 2026, ScienceLeadR ranks Carsten Bokemeyer in the top 1% of experts worldwide for Testicular Neoplasms, Testicular Diseases and Gonadal Disorders. Carsten Bokemeyer has authored 1,467 publications, the most recent in 2026, and is an investigator in 29 clinical trials, 2 of them ongoing. SLR score: 4,688 (community average: 125). How the SLR is computed.

LeadR Profile

Carsten Bokemeyer University Medical Center Hamburg-Eppendorf Germany
4 688 ScienceLeadR Reputation 4688

Unlock

Register Login
Network Map

Oncology

Subspecialties: Hematology - Biochemistry - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1992 - 2026
Source: PubMed

University Medical Center Hamburg-Eppendorf

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1467

Citations

Citations: 60 138 1st author: 133 Last author: 246 Unique author: 9

Main journals

J Clin Oncol 157
Ann Oncol 80
Blood 74
Eur J Cancer 58
Onkologe (Berl) 37

Best Journals

J Clin Oncol 33
Ann Oncol 12
N Engl J Med 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
ERG inhibition selectively sensitizes ERG-positive prostate cancer to radiation through DNA repair vulnerabilities and enhances response to androgen receptor inhibitors.
PMID 42926195 — cells, dna repair, androgens, receptors, androgen, neoplasms, prostate, organoids, proteomics, prostatic neoplasms, therapeutics, medical oncology, tissues, immunoblotting		J Exp Clin Cancer Res20260
Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature.
PMID 42853263 — cells, hematology, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, thyroid gland, therapeutics, b-lymphocytes		Ann Hematol20260
Insights into the survival impact of delayed immunochemotherapy in newly diagnosed diffuse large B-cell lymphoma: results from a nationwide registry study.
PMID 42791537 — registries, cells, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, neoplasms, diagnosis, therapeutics, b-lymphocytes		BMC Cancer20260
Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial.
PMID 42786443 — cells, neoplasms, multiple myeloma, therapeutics		BMC Cancer20260
Socioeconomic disparities in survival among follicular lymphoma patients.
PMID 42744922 — lymphoma, follicular, comorbidity, mortality, lymphoma		Sci Rep20260

Clinical Studies 29

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 10
Phase 2 9
N/A 4
Phase 1 3
Phase 1/Phase 2 3

By status:

Completed 20
Active not recruiting 4
Recruiting 3
Terminated 1
Unknown 1

By type:

Interventional 28
Observational 1

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 6
multicentric5to9 4
multicentricup10 12

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Existential Distress in Advanced Cancer Comparing a Short term Psychodynamic Psychotherapy (ORPHYS) to Treatment as Usual (TAU)
NCT07312760 — fantasy, constriction, pathologic, fear, neoplasms, psychotherapy, conflict, psychological, consciousness, psycho-oncology, uncertainty, unconscious, psychology, physicians, pyloric stenosis, therapeutics, psychosocial intervention, psychotherapy, psychodynamic, mentalization, pyloric stenosis, hypertrophic, demoralization		N/ARecruiting2025
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11 14) Multiple Myeloma
NCT05853965 — multiple myeloma, therapeutics		Phase 1/Phase 2Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS